中基長壽科學(00767.HK)訂立疫苗及抗生素特許經營權收購框架協議
中基長壽科學(00767.HK)公佈,與東展醫藥訂立特許經營權收購框架協議,公司將視乎獨立估值的結果,獨家收購東展醫藥擁有的疫苗及抗生素批發銷售權和西藥批發銷售權。
公司表示,收購後可立即獲得疫苗及抗生素之合法經營權,爲向國際市場大規模採購和大規模銷售奠定基礎。完成潛在收購後,公司並將組建與整合現有的生物製劑營銷管理團隊,建立全球特別是大中華區的疫苗、抗生素、長壽生物製劑等銷售網絡。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.